Definition

A preparation of autologous T lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) targeting sialic acid-binding immunoglobulin (Ig)-like lectin 6 (Siglec-6) and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon infusion back into the patient, autologous anti-Siglec-6 CAR-T cells target and bind to Siglec-6-expressing tumor cells, thereby inducing selective toxicity in Siglec-6-expressing tumor cells. Siglec-6 is overexpressed in certain malignancies, including acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), and not expressed in normal hematopoietic stem and progenitor cells (HSPCs).